Research programme: gene therapies - Biogen/Targeted GeneticsAlternative Names: Gene therapy research programme - Biogen/Targeted Genetics
Latest Information Update: 25 Mar 2017
At a glance
- Originator Biogen Idec; Targeted Genetics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec
- 15 Sep 2003 The 3-year collaboration between Biogen and Targeted Genetics ended upon completion
- 15 Sep 2003 Discontinued - Preclinical for Cancer in USA (unspecified route)